Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Holdings Raised by Traynor Capital Management Inc.

Traynor Capital Management Inc. boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1,038.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,762 shares of the pharmaceutical company’s stock after buying an additional 5,256 shares during the period. Traynor Capital Management Inc.’s holdings in Vertex Pharmaceuticals were worth $2,320,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in VRTX. EverSource Wealth Advisors LLC boosted its stake in Vertex Pharmaceuticals by 5.8% during the second quarter. EverSource Wealth Advisors LLC now owns 598 shares of the pharmaceutical company’s stock valued at $296,000 after buying an additional 33 shares in the last quarter. Public Sector Pension Investment Board lifted its holdings in Vertex Pharmaceuticals by 72.9% in the 2nd quarter. Public Sector Pension Investment Board now owns 9,844 shares of the pharmaceutical company’s stock valued at $4,614,000 after acquiring an additional 4,151 shares during the last quarter. Evergreen Capital Management LLC grew its stake in shares of Vertex Pharmaceuticals by 9.1% in the 2nd quarter. Evergreen Capital Management LLC now owns 2,636 shares of the pharmaceutical company’s stock worth $1,236,000 after purchasing an additional 220 shares during the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its stake in Vertex Pharmaceuticals by 60.3% during the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 49,474 shares of the pharmaceutical company’s stock valued at $23,189,000 after purchasing an additional 18,605 shares during the last quarter. Finally, Sfmg LLC increased its holdings in shares of Vertex Pharmaceuticals by 0.8% in the second quarter. Sfmg LLC now owns 7,845 shares of the pharmaceutical company’s stock valued at $3,677,000 after buying an additional 60 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $428.00 on Thursday. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The stock’s 50-day moving average is $438.10 and its 200-day moving average is $465.39. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The firm had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.69 billion. During the same quarter in the previous year, the business posted $3.67 EPS. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

VRTX has been the subject of several recent analyst reports. Jefferies Financial Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the stock from $500.00 to $550.00 in a report on Monday, December 9th. Oppenheimer cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 19th. Raymond James restated a “market perform” rating on shares of Vertex Pharmaceuticals in a report on Thursday, October 10th. JPMorgan Chase & Co. dropped their price target on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a research report on Monday, December 23rd. Finally, HC Wainwright decreased their price objective on Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating for the company in a research report on Friday, December 20th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $490.38.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.